Suscribirse

Platelet-activating factor, histamine, and tryptase levels in human anaphylaxis - 27/12/12

Doi : 10.1016/j.jaci.2012.08.016 
Peter Vadas, MD, PhD a, , Boris Perelman, PhD a, Gary Liss, MD, MS b
a Division of Allergy and Clinical Immunology, Department of Medicine, St Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada 
b Gage Occupational and Environmental Health Unit, Dalla Lama School of Public Health, University of Toronto, Toronto, Ontario, Canada 

Corresponding author: Peter Vadas, MD, PhD, Division of Allergy and Clinical Immunology, Department of Medicine, St Michael’s Hospital, University of Toronto, Carter Wing 8-161, 30 Bond St, Toronto, ON M5B IW8, Canada.

Abstract

Background

Platelet-activating factor (PAF) is an important mediator and correlates with anaphylaxis severity. How well PAF correlates with severity relative to histamine or tryptase is not known.

Objective

To analyze the levels of PAF, histamine, and tryptase as a function of severity in patients with acute allergic reactions.

Methods

PAF, histamine, and tryptase levels were measured in blood samples collected from 23 healthy volunteers and from 41 patients during acute allergic reactions. Reactions were stratified by severity from grade 1 (least severe) to grade 3 (most severe).

Results

Among the 3 reaction grades, there were significant differences by ANOVA for PAF (P < .0001). The proportion of elevated PAF values increased across severity groups (P = .0009). Increased PAF levels were observed in 20%, 66.7%, and 100% of the patients with grades 1, 2, and 3 allergic reactions, respectively. While the proportion of elevated histamine values increased from 40% to 57% to 70% across grades 1, 2, and 3, respectively, these were not significantly different (P = .40). For tryptase, the proportion of elevated values increased monotonically from 0 in grade 1 to 4.8% in grade 2 to 60% in grade 3 (P = .0002).

Conclusions

The PAF level was significantly elevated in proportion to the severity of acute allergic reactions. Whereas the PAF level was elevated in all patients with severe anaphylaxis, this was not true for either histamine or tryptase. Neither histamine nor tryptase showed as good correlations with severity scores as did PAF. These data are consistent with a pivotal role for PAF as a mediator of anaphylaxis.

El texto completo de este artículo está disponible en PDF.

Key words : Platelet-activating factor, histamine, tryptase, anaphylaxis, emergency department

Abbreviations used : PAF, PAF-AH


Esquema


 This study was supported by grants-in-aid from the National Peanut Board and the Ganz Family Foundation.
 Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest.


© 2012  American Academy of Allergy, Asthma & Immunology. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 131 - N° 1

P. 144-149 - janvier 2013 Regresar al número
Artículo precedente Artículo precedente
  • Identifying infants at high risk of peanut allergy: The Learning Early About Peanut Allergy (LEAP) screening study
  • George Du Toit, Graham Roberts, Peter H. Sayre, Marshall Plaut, Henry T. Bahnson, Herman Mitchell, Suzana Radulovic, Susan Chan, Adam Fox, Victor Turcanu, Gideon Lack, Learning Early About Peanut Allergy (LEAP) Study Team
| Artículo siguiente Artículo siguiente
  • Parent report of physician diagnosis in pediatric food allergy
  • Ruchi S. Gupta, Elizabeth E. Springston, Bridget Smith, Jacqueline Pongracic, Jane L. Holl, Manoj R. Warrier

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.